MedDataX Logo

Nasal and Systemic Immune Responses to Nasal Influenza Vaccine

NCT ID: NCT04110366

Last Updated: 2021-12-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-14

Study Completion Date

2020-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK. It is also licensed to be given to adults up to the age of 49 years in the USA. The systems biology of the human blood response to influenza vaccines has been studied in great detail, but there is a paramount need to study innate and specific, soluble and cellular immune responses at the nasal mucosal site of influenza infection. In this way this study aims to determine correlates of efficacy and vaccine take in serum and nasal mucosal lining fluid (MLF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will collect serial samples prior to vaccination and at intervals up to day 28 post-vaccination to establish the kinetics of the nasal mucosal and blood systemic response to LAIV in young adults aged 18-30 years (n=40). In the nose the investigators will measure viral load, soluble mediators of inflammation and antibodies (humoral immunity) in mucosal lining fluid; while cellular immune responses and serology will be assessed in blood samples. Investigators at Imperial College London (ICL) have been involved in the development of novel methods of non-invasive precision mucosal sampling, including absorption of MLF from the nose by nasosorption. The investigators have also developed assays for influenza-specific IgA by ELISA, and aim to compare this assay against a repertoire of serological assays in patients after LAIV administration.

The study will precisely assess mucosal and systemic immune responses to the LAIV nasal vaccine.

The primary endpoint will be based on nasal mucosal levels of IgA and IgG antibodies to the 4 constituent viral subtypes in LAIV: measured by ELISA and multiplex immunoassay (Mesoscale Diagnostics) and expressed as seroconversion rates, geometric mean titre (GMT) changes, and geometric mean fold rises (GMFR). The secondary endpoints will be: (1) haemagglutination inhibition (HAI) assay titres measured in serum and the nose, (2) influenza pseudotype neutralisation by antibodies in serum and the nose, (3) nasal cytokine and chemokine levels as measured by immunoassay and (4) nasal viral load quantified by qPCR.

It is thought that the immune response to LAIV in an individual is mediated by a combination of mucosal and systemic factors, involving innate and specific mechanisms that have different kinetics, and various cell types. By understanding the molecular and cellular basis of the nasal mucosal response to LAIV, the investigators hope to identify key molecular signatures and biomarkers associated with LAIV responses, and to assess protective pathways that could be stimulated by novel vaccines. The nasal vaccine challenge model could be used to test other new vaccines, and proceed to rational development of improved vaccines for influenza and other diseases. Furthermore nasal mucosal methods could be used in the clinic to identify subjects who have responded poorly to vaccines, or to assess vaccine efficacy in large populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Vaccine Virus Shedding

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

influenza vaccine virus antibody cytokine respiratory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Live attenuated influenza vaccine

Participants receiving live attenuated influenza vaccine (LAIV)

Group Type EXPERIMENTAL

Live attenuated influenza vaccine

Intervention Type BIOLOGICAL

Vaccination with live attenuated influenza vaccine (LAIV)

Mucosal immune stability cohort

Participants receiving a vehicle control nasal challenge

Group Type EXPERIMENTAL

Vehicle control

Intervention Type OTHER

Vehicle control nasal challenge

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Live attenuated influenza vaccine

Vaccination with live attenuated influenza vaccine (LAIV)

Intervention Type BIOLOGICAL

Vehicle control

Vehicle control nasal challenge

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluenz

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Capacity to provide written informed consent
* Aged 18-30 years (inclusive)
* Fluent English speaker

Exclusion Criteria

* Current involvement in another study unless observational or in follow-up phase (non-interventional)
* Received any influenza vaccine over the last 2 years
* Egg allergy
* Previous significant adverse reaction to any vaccination/immunisation
* Current regular (daily) smoker
* Pregnant
* Any medication that may affect the immune system (e.g. steroids)
* Taking regular acetylsalicylic acid (aspirin)
* Unable to give informed consent
* Current acute severe febrile illness
* Taking long term antibiotics
* Clinically diagnosed influenza in the last 2 years
* Any long-term health problem with heart disease, lung disease (including asthma), kidney disease, neurologic disease, liver disease, metabolic disease (e.g. diabetes) or anemia or another blood disorder
* Use of drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis or anticancer drugs; or radiation treatments
* History of Guillain-Barre syndrome
* Live with or expect to have close contact with a person whose immune system is severely compromised and who must be in protective isolation (e.g., an isolation room of a bone marrow transplant unit)
* Received any other vaccinations in the past 4 weeks
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Imperial College Healthcare NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter J Openshaw, PhD

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Trevor T Hansel, PhD

Role: STUDY_DIRECTOR

Imperial College London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imperial Clinical Respiratory Research Unit

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Thwaites RS, Uruchurtu ASS, Negri VA, Cole ME, Singh N, Poshai N, Jackson D, Hoschler K, Baker T, Scott IC, Ros XR, Cohen ES, Zambon M, Pollock KM, Hansel TT, Openshaw PJM. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. Nat Commun. 2023 Dec 5;14(1):8053. doi: 10.1038/s41467-023-43842-7.

Reference Type DERIVED
PMID: 38052824 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18/LO/0904

Identifier Type: -

Identifier Source: org_study_id